Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer

Clinical trial NCT06035679 · RECRUITING

Trial details

NCT number: NCT06035679
Sponsor: Youzhi Zhu
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Breast Cancer Female

Start date: 2023-08-17
Primary completion: 2026-11-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.